We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+18.77%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$5.81B
AUM Growth
+$81.2M
Cap. Flow
-$585M
Cap. Flow %
-10.08%
Top 10 Hldgs %
85.45%
Holding
128
New
20
Increased
23
Reduced
35
Closed
17

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$7.13M
2
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$6.85M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.62M
4
PRQR icon
ProQR Therapeutics
PRQR
+$5.19M
5
ARRY
Array Biopharma Inc
ARRY
+$5.11M

Top Sells

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$22.6M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$15M
3
ONC
BeOne Medicines Ltd
ONC
+$13M
4
BLUE
bluebird bio
BLUE
+$12.4M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$12.2M

Sector Composition

Rank Sector Weight
1 Consumer Staples 42.79%
2 Consumer Discretionary 22.09%
3 Healthcare 21.32%
4 Financials 0%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
26
DELISTED
Array Biopharma Inc
ARRY
$18.4M 0.32%
1,500,000
+550,000
+58% +$5.11M
INCY icon
27
CALL
Incyte
INCY
$24.4B
$17.5M 0.3%
150,000
-50,000
-25% -$6.33M
FOLD
28
CALL
DELISTED
Amicus Therapeutics
FOLD
$15.1M 0.26%
1,000,000
+500,000
+100% +$6.61M
MS icon
29
CALL
Morgan Stanley
MS
$343B
$14.5M 0.25%
300,000
-200,000
-40% -$9.28M
NKTR icon
30
CALL
Nektar Therapeutics
NKTR
$2.57B
$14.4M 0.25%
40,000
-26,667
-40% -$8.34M
RDUS
31
CALL
DELISTED
Radius Health, Inc.
RDUS
$13.5M 0.23%
350,000
+150,000
+75% +$5.89M
TER icon
32
CALL
Teradyne
TER
$64.2B
$13.1M 0.22%
350,000
-150,000
-30% -$5.19M
IRWD icon
33
Ironwood Pharmaceuticals
IRWD
$674M
$12.9M 0.22%
975,354
+238,800
+32% +$3.29M
WUBA
34
CALL
DELISTED
58.com Inc
WUBA
$12.6M 0.22%
+200,000
New +$11.4M
ARRY
35
CALL
DELISTED
Array Biopharma Inc
ARRY
$12.3M 0.21%
1,000,000
+500,000
+100% +$4.64M
AVXS
36
DELISTED
AveXis, Inc. Common Stock
AVXS
$11.6M 0.2%
120,000
-20,000
-14% -$1.8M
RXDX
37
DELISTED
Ignyta, Inc.
RXDX
$11.1M 0.19%
900,000
– –
MDCO
38
DELISTED
Medicines Co
MDCO
$11.1M 0.19%
300,000
-50,000
-14% -$1.84M
AGEN
39
Agenus
AGEN
$315M
$11M 0.19%
127,375
+25,475
+25% +$2.06M
FOLD
40
DELISTED
Amicus Therapeutics
FOLD
$10.6M 0.18%
700,000
-700,000
-50% -$9.26M
ATRA icon
41
Atara Biotherapeutics
ATRA
$76.7M
$9.93M 0.17%
24,000
+4,000
+20% +$1.51M
TSRO
42
DELISTED
TESARO, Inc.
TSRO
$9.68M 0.17%
75,000
+25,000
+50% +$3.1M
RDUS
43
DELISTED
Radius Health, Inc.
RDUS
$9.64M 0.17%
250,000
+100,000
+67% +$3.93M
CLVS
44
DELISTED
Clovis Oncology, Inc.
CLVS
$9.48M 0.16%
115,000
+90,000
+360% +$7.13M
SAGE
45
DELISTED
Sage Therapeutics
SAGE
$9.35M 0.16%
150,000
+60,000
+67% +$4.71M
GBT
46
DELISTED
Global Blood Therapeutics, Inc.
GBT
$9.31M 0.16%
300,000
+200,000
+200% +$5.62M
BMRN icon
47
CALL
BioMarin Pharmaceuticals
BMRN
$13.3B
$9.31M 0.16%
100,000
-50,000
-33% -$4.42M
SRPT icon
48
Sarepta Therapeutics
SRPT
$1.95B
$9.07M 0.16%
200,000
+50,000
+33% +$2M
JUNO
49
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
$8.97M 0.15%
200,000
+150,000
+300% +$5.11M
MCRB icon
50
Seres Therapeutics
MCRB
$45M
$8.82M 0.15%
27,500
-2,500
-8% -$683K
1
2
3 4 5

Similar funds

GP
Greenline Partners New York $930M AUM 29.59% 1-Year Est. Return
BCC
Biglari Capital Corp San Antonio, Texas $929M AUM 39.8% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
ICM
Innovator Capital Management Wheaton, Illinois $925M AUM 49.11% 1-Year Est. Return
OCM
OLP Capital Management Causeway Bay, Hong Kong $942M AUM 5.25% 1-Year Est. Return

Artal Group's Q3 2017 Portfolio in Review

As of Q3 2017, Artal Group held 128 positions worth $5.81B, up 1.4% from $5.72B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Artal Group withdrew a net $585M in Q3 2017, closing 17 positions and reducing 35 holdings. Its most notable exit was Goldman Sachs, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 43% of assets, up from 35% a quarter earlier, followed by Consumer Discretionary and Healthcare.

Against the trend, Artal Group opened a new position in Achillion Pharmaceuticals worth $4.49M.

  • Artal Group's largest Q3 2017 buy was Achillion Pharmaceuticals: 1,000,000 shares worth $4.49M.
  • Artal Group added most to Clovis Oncology, Inc. in Q3 2017, an estimated $7.13M increase.
  • Artal Group's biggest Q3 2017 reduction was Agios Pharmaceuticals, cutting an estimated $15M.
  • Artal Group fully exited Goldman Sachs in Q3 2017, selling an estimated $22.6M.
  • Artal Group's ten largest holdings make up 85% of its $5.81B portfolio in Q3 2017.
  • Artal Group opened 20 new positions and closed 17 in Q3 2017.
  • Artal Group's portfolio value rose 1.4% quarter-over-quarter to $5.81B.

Based on Artal Group's 13F filing for Q3 2017, filed 8 Nov 2017.